Atezolizumab and Bevacizumab Improves Survival With Unresectable Hepatocellular Carcinoma

New treatments for unresectable hepatocellular carcinoma (HCC) were approved based on a Phase 3 clinical trial. Richard Kim has recently provided an overview of this study. The Study This study ultimately…

Continue Reading Atezolizumab and Bevacizumab Improves Survival With Unresectable Hepatocellular Carcinoma
Wake Forest Baptist Comprehensive Cancer Center Receives $2.5M Grant for Organoid Research
stevepb / Pixabay

Wake Forest Baptist Comprehensive Cancer Center Receives $2.5M Grant for Organoid Research

  Recently, the National Cancer Institute provided a $2.5M grant to support specialized medical research being performed at the Wake Forest Organoid Research Center (WFORCE). According to the press release,…

Continue Reading Wake Forest Baptist Comprehensive Cancer Center Receives $2.5M Grant for Organoid Research
Data Supports Tesamorelin as Effective for HIV-Associated NASH
Arcaion / Pixabay

Data Supports Tesamorelin as Effective for HIV-Associated NASH

  Biopharmaceutical company Theratechnologies Inc. recently announced that its therapy candidate tesamorelin is effective in the treatment of HIV-associated nonalcoholic steatohepatitis (NASH). According to new data, published in JCI Insight, tesamorelin…

Continue Reading Data Supports Tesamorelin as Effective for HIV-Associated NASH
Alpha-1 Antitrypsin Deficiency Treatment Receives Orphan Drug Designation
source: pixabay.com

Alpha-1 Antitrypsin Deficiency Treatment Receives Orphan Drug Designation

  In June 2019, Dicerna Pharmaceuticals submitted a clinical trial application for their DCR-A1AT therapy and expects to treat the first patient with A1AD-related liver disease near the end of…

Continue Reading Alpha-1 Antitrypsin Deficiency Treatment Receives Orphan Drug Designation
Health Canada Approves Cabometyx for Previously Treated Hepatocellular Carcinoma
ArtTower / Pixabay

Health Canada Approves Cabometyx for Previously Treated Hepatocellular Carcinoma

According to a story from the Malvern Daily Record, the biotechnology company Exelixis, Inc. has recently announced that its partner company Ipsen BioPharmaceuticals Canada Inc. has had its drug cabozantinib…

Continue Reading Health Canada Approves Cabometyx for Previously Treated Hepatocellular Carcinoma
Positive Preliminary Safety Findings in Phase 2 Hepatocellular Carcinoma Trial
DarkoStojanovic / Pixabay

Positive Preliminary Safety Findings in Phase 2 Hepatocellular Carcinoma Trial

According to a story from BioPortfolio, the biotechnology company Tiziana Life Sciences plc has announced the release of preliminary topline data findings from its phase 2a clinical trial, which tested…

Continue Reading Positive Preliminary Safety Findings in Phase 2 Hepatocellular Carcinoma Trial

New Treatment Approved by FDA for Rare Form of Hepatocellular Carcinoma

The FDA has just recently approved CYRAMZA as a treatment for those with hepatocellular carcinoma (HCC), who have been treated with sorafenib, and who have ≥400 ng/mL of alpha-fetoprotein (AFP).…

Continue Reading New Treatment Approved by FDA for Rare Form of Hepatocellular Carcinoma
Analysis of Hepatocellular Carcinoma Trial Presented at 2019 Gastrointestinal Cancers Symposium
MariSmithPix / Pixabay

Analysis of Hepatocellular Carcinoma Trial Presented at 2019 Gastrointestinal Cancers Symposium

According to a story from finanzen.ch, the pharmaceutical company Eisai, Inc. announced that that company presented a total of four abstracts which were related to a Phase 3 clinical trial…

Continue Reading Analysis of Hepatocellular Carcinoma Trial Presented at 2019 Gastrointestinal Cancers Symposium

Early Trial Data Suggests Safety and Potential Efficacy of Experimental Drug in Treating Advanced Hepatocellular Carcinoma

According to a story from BioPortfolio, the biotechnology company Tiziana Life Sciences plc recently announced encouraging results from an interim safety review of the company's Phase 2a clinical trial. This…

Continue Reading Early Trial Data Suggests Safety and Potential Efficacy of Experimental Drug in Treating Advanced Hepatocellular Carcinoma
FDA Approves Drug for Previously Treated Hepatocellular Carcinoma Patients
Source: Pixabay.com

FDA Approves Drug for Previously Treated Hepatocellular Carcinoma Patients

According to an article from Global Banking & Financing Review, the California-based pharmaceutical company Exelixis, Inc. has announced the FDA's approval of their drug Cabometyx (cabozantinib) for patients previously diagnosed…

Continue Reading FDA Approves Drug for Previously Treated Hepatocellular Carcinoma Patients
Proof of Concept Study Demonstrates Potential Treatment for Metastatic Hepatocellular Carcinoma
Bru-nO / Pixabay

Proof of Concept Study Demonstrates Potential Treatment for Metastatic Hepatocellular Carcinoma

According to a story from bioportfolio.com, the biopharmaceutical company Eureka Therapeutics recently released the results of the proof of concept trial for its experimental T-cell therapy ET140202 as a treatment…

Continue Reading Proof of Concept Study Demonstrates Potential Treatment for Metastatic Hepatocellular Carcinoma
Hepatocellular Carcinoma Patient’s Twin Sister is Fundraising for £80,000 Treatment
nattanan23 / Pixabay

Hepatocellular Carcinoma Patient’s Twin Sister is Fundraising for £80,000 Treatment

According to a story from the St. Helens Star, Amanda Sackville-Wiggins was diagnosed with hepatocellular carcinoma, a rare type of liver cancer, just after her 21st birthday. The cancer was…

Continue Reading Hepatocellular Carcinoma Patient’s Twin Sister is Fundraising for £80,000 Treatment